These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11583336)

  • 1. Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin.
    Margaglione M; Brancaccio V; Ciampa A; Di Minno G
    Thromb Haemost; 2001 Sep; 86(3):938. PubMed ID: 11583336
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic modulation of oral anticoagulation with warfarin.
    Margaglione M; Colaizzo D; D'Andrea G; Brancaccio V; Ciampa A; Grandone E; Di Minno G
    Thromb Haemost; 2000 Nov; 84(5):775-8. PubMed ID: 11127854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avoiding overanticoagulation: pharmacogenomics or pragmatism?
    Baglin T
    Thromb Haemost; 2001 May; 85(5):945-6. PubMed ID: 11372698
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetic susceptibility to hemorrhagic complications during warfarin therapy.
    Tabrizi AR; Freeman BD; Buchman TG; Zehnbauer BA
    Surgery; 2001 May; 129(5):645-6. PubMed ID: 11331459
    [No Abstract]   [Full Text] [Related]  

  • 5. Interindividual variability in sensitivity to warfarin--Nature or nurture?
    Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
    Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic control of anticoagulation.
    Mannucci PM
    Lancet; 1999 Feb; 353(9154):688-9. PubMed ID: 10073506
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
    Aithal GP; Day CP; Kesteven PJ; Daly AK
    Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin dose requirement and CYP2C9 polymorphisms.
    Halkin H; Lubetsky A
    Lancet; 1999 Jun; 353(9168):1972-3. PubMed ID: 10371596
    [No Abstract]   [Full Text] [Related]  

  • 9. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.
    Ablin J; Cabili S; Lagziel A; Peretz H
    Isr Med Assoc J; 2002 Feb; 4(2):139-41. PubMed ID: 11875991
    [No Abstract]   [Full Text] [Related]  

  • 10. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
    Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
    JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.
    Takahashi H; Ishikawa S; Nomoto S; Nishigaki Y; Ando F; Kashima T; Kimura S; Kanamori M; Echizen H
    Clin Pharmacol Ther; 2000 Nov; 68(5):541-55. PubMed ID: 11103757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C9 polymorphism and warfarin dose requirements.
    Daly AK; Day CP; Aithal GP
    Br J Clin Pharmacol; 2002 Apr; 53(4):408-9. PubMed ID: 11966680
    [No Abstract]   [Full Text] [Related]  

  • 13. Major bleeding caused by warfarin in a genetically susceptible patient.
    Bloch A; Ben-Chetrit E; Muszkat M; Caraco Y
    Pharmacotherapy; 2002 Jan; 22(1):97-101. PubMed ID: 11794436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype.
    Dericioglu N; Babaoglu MO; Saygi S; Bozkurt A; Yasar U
    Ann Pharmacother; 2004 May; 38(5):899. PubMed ID: 15039471
    [No Abstract]   [Full Text] [Related]  

  • 15. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.
    Takahashi H; Sato T; Shimoyama Y; Shioda N; Shimizu T; Kubo S; Tamura N; Tainaka H; Yasumori T; Echizen H
    Clin Pharmacol Ther; 1999 Dec; 66(6):569-81. PubMed ID: 10613612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
    Kim JS; Nafziger AN; Gaedigk A; Dickmann LJ; Rettie AE; Bertino JS
    J Clin Pharmacol; 2001 Jul; 41(7):715-22. PubMed ID: 11452703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.
    Takahashi H; Wilkinson GR; Padrini R; Echizen H
    Clin Pharmacol Ther; 2004 May; 75(5):376-80. PubMed ID: 15116049
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
    Furuya H; Fernandez-Salguero P; Gregory W; Taber H; Steward A; Gonzalez FJ; Idle JR
    Pharmacogenetics; 1995 Dec; 5(6):389-92. PubMed ID: 8747411
    [No Abstract]   [Full Text] [Related]  

  • 19. Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction.
    Kunze KL; Trager WF
    Drug Metab Dispos; 1996 Apr; 24(4):429-35. PubMed ID: 8801058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.
    Taube J; Halsall D; Baglin T
    Blood; 2000 Sep; 96(5):1816-9. PubMed ID: 10961881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.